Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Lupus ; 31(14): 1691-1705, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36036891

RESUMEN

Systemic lupus erythematosus (SLE) is an autoimmune disorder with significant health disparities, as it disproportionately and more severely affects vulnerable and disadvantaged population groups in the United States and around the world, that is, women, ethnic minorities, individuals living in poverty, less educated, and lacking medical insurance. Both, genetic and non-genetic factors, contribute to these disparities. To overcome these health disparities and reduce poor outcomes among disadvantaged SLE populations, interventions on non-genetic amendable factors, especially on social health determinants, are necessary.


Asunto(s)
Etnicidad , Lupus Eritematoso Sistémico , Humanos , Estados Unidos/epidemiología , Femenino
2.
Rheum Dis Clin North Am ; 47(1): 55-64, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-34042054

RESUMEN

The Lupus in Minorities: Nature Vs Nurture (LUMINA) cohort has placed Hispanics on the lupus map in the United States. Texan Hispanic and African American patients experience, overall, worse outcomes than the Caucasian and Puerto Rican Hispanic patients. The genetic component of ethnicity is important early in the disease course whereas socioeconomic factors become more important subsequently. The role of hydroxychloroquine in preventing damage accrual and reducing mortality in lupus patients is a major contribution of LUMINA.


Asunto(s)
Lupus Eritematoso Sistémico , Población Blanca , Negro o Afroamericano , Estudios de Cohortes , Hispánicos o Latinos , Humanos , Factores de Riesgo , Estados Unidos
3.
Int J Rheum Dis ; 21(11): 2019-2027, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29611343

RESUMEN

OBJECTIVE: To study the prevalence and the associated factors of work disability (WD) in systemic lupus erythematosus (SLE) patients. METHODS: A sample of 419 SLE patients from an observational cross-sectional multicenter study was included. Sociodemographic features, disease characteristics, comorbidities, quality of life, unhealthy behaviors, and work-related factors were measured in a standardized interview. Work disability was defined by patient self-report of not being able to work because of SLE. To identify variables associated with work disability, two different multivariate regression models using a stepwise backward method were performed. RESULTS: Prevalence of WD due to SLE was 24.3%. Eighty-nine percent were female and 51% were Caucasians. Mean disease duration was 8.9 ± 7.2 years, and median System Lupus International Collaborating Clinics/American College of Rheumatology damage index SLICC-SDI was 1.5 (range 0-17). In stepwise multivariate logistic regression, living below the poverty line (odds ratio [OR] = 4.65), less than 12 years of education (OR = 2.84), Mestizo ethnicity (OR = 1.94) and SLICC-SDI (OR = 1.25) were predictors of WD. A second model was performed including patient-derived measures; in this model sedentary lifestyle (OR = 2.69) and lower emotional health domain score of the Lupus Quality of Life (LupusQoL) questionnaire (OR = 1.03) were found to be associated to WD and a higher score in LupusQoL physical health domain (OR = 0.93) was protective. CONCLUSION: The prevalence of WD in Argentinian SLE patients was 24.3%. WD was associated with ethnic (Mestizo), socioeconomic (poverty) and disease-related factors. Patient-related outcomes such us sedentary lifestyle and poor emotional quality of life were also associated with WD.


Asunto(s)
Absentismo , Evaluación de la Discapacidad , Indígenas Sudamericanos , Lupus Eritematoso Sistémico/etnología , Ausencia por Enfermedad , Determinantes Sociales de la Salud , Factores Socioeconómicos , Adulto , Argentina/epidemiología , Estudios Transversales , Emociones , Femenino , Estado de Salud , Humanos , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/psicología , Lupus Eritematoso Sistémico/terapia , Masculino , Salud Mental , Persona de Mediana Edad , Pobreza , Prevalencia , Calidad de Vida , Factores de Riesgo , Conducta Sedentaria , Adulto Joven
4.
J Rheumatol ; 44(12): 1804-1812, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29093158

RESUMEN

OBJECTIVE: To define whether Amerindian genetic ancestry correlates with clinical and therapeutic variables in admixed individuals with rheumatoid arthritis (RA) from Latin America. METHODS: Patients with RA (n = 1347) and healthy controls (n = 1012) from Argentina, Mexico, Chile, and Peru were included. Samples were genotyped for the Immunochip v1 using the Illumina platform. Clinical data were obtained through interviews or the clinical history. RESULTS: Percentage of Amerindian ancestry was comparable between cases and controls. Morning stiffness (p < 0.0001, OR 0.05), rheumatoid factor (RF; p < 0.0001, OR 0.22), radiographic changes (p < 0.0001, OR 0.05), and higher number of criteria were associated with lower Amerindian ancestry after Bonferroni correction. Higher Amerindian ancestry correlated only with weight loss (pBonferroni < 0.0001, OR 2.85). Increased Amerindian ancestry correlated with higher doses of azathioprine (p < 0.0001, OR 163.6) and sulfasalazine (p < 0.0001, OR 48.6), and inversely with methotrexate (p = 0.001, OR 0.35), leflunomide (p = 0.001, OR 0.16), and nonsteroidal antiinflammatory drugs (pBonferroni = 0.001, OR 0.37). Only the presence of RF and weight loss were modified after confounders adjustment. CONCLUSION: Amerindian ancestry protects against most major clinical criteria of RA, but regarding the association of RF with increased European ancestry, age, sex, and smoking are modifiers. Ancestry also correlates with the therapeutic profiles.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Antirreumáticos/uso terapéutico , Artritis Reumatoide/genética , Genotipo , Factor Reumatoide/genética , Adulto , Factores de Edad , Anciano , Alelos , Argentina , Artritis Reumatoide/diagnóstico por imagen , Artritis Reumatoide/tratamiento farmacológico , Chile , Femenino , Humanos , Indígenas Norteamericanos , Indígenas Sudamericanos , Isoxazoles/uso terapéutico , Leflunamida , Masculino , Metotrexato/uso terapéutico , México , Persona de Mediana Edad , Perú , Radiografía , Factores Sexuales , Sulfasalazina/uso terapéutico
5.
Arthritis Rheumatol ; 68(4): 932-43, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26606652

RESUMEN

OBJECTIVE: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a strong genetic component. We undertook the present work to perform the first genome-wide association study on individuals from the Americas who are enriched for Native American heritage. METHODS: We analyzed 3,710 individuals from the US and 4 countries of Latin America who were diagnosed as having SLE, and healthy controls. Samples were genotyped with HumanOmni1 BeadChip. Data on out-of-study controls genotyped with HumanOmni2.5 were also included. Statistical analyses were performed using SNPtest and SNPGWA. Data were adjusted for genomic control and false discovery rate. Imputation was performed using Impute2 and, for classic HLA alleles, HiBag. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. RESULTS: The IRF5-TNPO3 region showed the strongest association and largest OR for SLE (rs10488631: genomic control-adjusted P [Pgcadj ] = 2.61 × 10(-29), OR 2.12 [95% CI 1.88-2.39]), followed by HLA class II on the DQA2-DQB1 loci (rs9275572: Pgcadj = 1.11 × 10(-16), OR 1.62 [95% CI 1.46-1.80] and rs9271366: Pgcadj = 6.46 × 10(-12), OR 2.06 [95% CI 1.71-2.50]). Other known SLE loci found to be associated in this population were ITGAM, STAT4, TNIP1, NCF2, and IRAK1. We identified a novel locus on 10q24.33 (rs4917385: Pgcadj = 1.39 × 10(-8)) with an expression quantitative trait locus (eQTL) effect (Peqtl = 8.0 × 10(-37) at USMG5/miR1307), and several new suggestive loci. SLE risk loci previously identified in Europeans and Asians were corroborated. Local ancestry estimation showed that the HLA allele risk contribution is of European ancestral origin. Imputation of HLA alleles suggested that autochthonous Native American haplotypes provide protection against development of SLE. CONCLUSION: Our results demonstrate that studying admixed populations provides new insights in the delineation of the genetic architecture that underlies autoimmune and complex diseases.


Asunto(s)
Indio Americano o Nativo de Alaska/genética , Lupus Eritematoso Sistémico/genética , Argentina , Antígeno CD11b/genética , Estudios de Casos y Controles , Chile , Cromosomas Humanos Par 10/genética , Proteínas de Unión al ADN/genética , Femenino , Predisposición Genética a la Enfermedad , Estudio de Asociación del Genoma Completo , Antígenos HLA-DQ/genética , Cadenas beta de HLA-DQ/genética , Haplotipos , Humanos , Factores Reguladores del Interferón , Quinasas Asociadas a Receptores de Interleucina-1/genética , Masculino , México , ATPasas de Translocación de Protón Mitocondriales/genética , NADPH Oxidasas/genética , Oportunidad Relativa , Perú , Análisis de Componente Principal , Factor de Transcripción STAT4/genética , Estados Unidos , Población Blanca/genética , beta Carioferinas
6.
Rheumatol Int ; 35(1): 107-14, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24948375

RESUMEN

To determine the prevalence of and associated factors to work instability (WI) in rheumatoid arthritis (RA) Argentinean patients. Observational cross-sectional study that assessing employment status in currently working RA patients. They answered the validated version of RA work instability scale (RA-WIS). High-risk WI was considered when RA-WIS was ≥17. Factors associated with high-risk WI were examined by univariable and multivariable analysis. Four-hundred and fifty RA patients were enrolled; of these, 205 patients were currently employed, but only 172 have completed questionnaires required [RA-WIS and health assessment questionnaire (HAQ-A)]. Their mean age was 49.3 ± 10.8 years; 81.3 % were female; and their mean disease duration was 8.1 ± 7.2 years. Fifty-two percent of patients were doing manual work. The mean RA-WIS score was 11.4 ± 6.8, and 41 % of patients had a high-risk WI. High-risk WI was associated with radiographic erosions (p < 0.001) and HAQ-A >0.87 (p < 0.001) in the univariable analysis, whereas in the multivariable logistic regression analysis the variables associated with a high-risk WI were as follows: HAQ-A >0.87 [odds ratio (OR) 12.31; 95 % CI 5.38-28.18] and the presence of radiographic erosions (OR 4.848; 95 % CI 2.22-10.5). In this model, having a higher monthly income (OR 0.301; 95 % CI 0.096-0.943) and a better functional class (OR 0.151; 95 % CI 0.036-0.632) were protective. Forty-one percent of RA working patients had high-risk WI. The predictors of high RA-WIS were HAQ-A ≥0.87 and radiographic erosions, whereas having a better functional class and have higher incomes were protective.


Asunto(s)
Artritis Reumatoide , Evaluación de la Discapacidad , Empleo , Adulto , Argentina , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios
7.
Rheum Dis Clin North Am ; 40(3): 433-54, vii-viii, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25034155

RESUMEN

Genetic factors seem to play a more important role early in the course of systemic lupus erythematosus (SLE), whereas nongenetic factors seem to play a more important role over the course of the disease. SLE is more frequent with less favorable outcomes in nonwhite populations. To overcome these differences and reduce the immediate-term, mediate-term, and long-term impact of SLE among disadvantaged populations, it is essential to increase disease awareness, to improve access to health care and to provide care to these patients in a consistent manner regardless of the severity of their disease.


Asunto(s)
Predisposición Genética a la Enfermedad , Lupus Eritematoso Sistémico , Farmacogenética , Etnicidad , Disparidades en el Estado de Salud , Humanos , Riñón/fisiopatología , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/epidemiología , Lupus Eritematoso Sistémico/genética , Lupus Eritematoso Sistémico/fisiopatología , Lupus Eritematoso Sistémico/terapia , Gravedad del Paciente , Pronóstico , Terapia de Reemplazo Renal/métodos
8.
J Clin Rheumatol ; 19(6): 329-31, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23965483

RESUMEN

The first annual meeting of the Latin American Spondyloarthritis Society for Education and Research in Immunology and Medicine (LASSERIM) was held in Bogotá, Colombia, in September 2012 and was attended by key opinion leaders, researchers, and rheumatologists. The meeting included presentations and discussions from renowned speakers during 2 days and a coaching leadership exercise led by an expert in the field followed by an open forum. Two groups defined a priori discussed the establishment of a professional network and organization to be involved in the identification, assessment, and effective resolution of health care issues in Latin America.A broad spectrum of topics were discussed but focused on the following: pharmacoeconomics in general rheumatology, spondyloarthritis and chronic back pain, therapeutic interventions in rheumatoid arthritis, ultrasonography in spondyloarthritis, impact of social media in medicine and global trends in leadership, quality of life, and innovation. A special workshop on coaching in health care and coaching as a tool to implement LASSERIM goals was part of the 2-day conference.LASSERIM will be working in the future on education, research, and innovation in the field of rheumatology and immunology. A special focus will be on spondyloarthritis, by promoting research, open discussions, and by conducting carefully planned research studies to impact on the quality of life of patients and doctors from Latin American countries.


Asunto(s)
Investigación Biomédica/tendencias , Reumatología/educación , Espondiloartritis/epidemiología , Espondiloartritis/terapia , Colombia , Atención a la Salud , Economía Farmacéutica , Humanos , América Latina/epidemiología , Calidad de Vida , Espondiloartritis/diagnóstico por imagen , Ultrasonografía
9.
J Rheumatol ; 39(11): 2216-9, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23118292

RESUMEN

OBJECTIVE: To determine the presence of psoriasis and psoriatic arthritis (PsA) in aboriginal people living in the Andean Mountains of Peru. METHODS: Consecutive patients with psoriasis and PsA attending an arthritis clinic in Juliaca, Puno, Peru, located 3824 m above sea level were examined. The CASPAR (ClASsification of Psoriatic ARthritis) criteria were used for classification of PsA. Diagnosis of psoriasis was confirmed by a dermatologist. RESULTS: Seventeen patients [11 (65%) men and 6 (35%) women] fulfilled classification criteria for PsA; one patient was of European ancestry and is not included in this report. Of the 16 aboriginal patients in this report, 5 were natives of Quechua ancestry and one was native Aymara. At the time of their first clinic visit, no native patient with PsA had a family history of psoriasis or PsA, and all patients exhibited an established disease of long duration and severity. Methotrexate was the drug of choice for all patients; 2 patients are currently receiving biological therapy. CONCLUSION: Contrary to what has been reported in the literature, both psoriasis and PsA are present in aboriginal people from the Andean Mountains of Peru. More studies are needed to further define the phenotype of these disorders, as well as the pathogenetic role of genetic and environmental factors.


Asunto(s)
Artritis Psoriásica/etnología , Artritis Psoriásica/epidemiología , Grupos de Población/etnología , Psoriasis/etnología , Psoriasis/epidemiología , Adulto , Anciano , Antirreumáticos/uso terapéutico , Artritis Psoriásica/tratamiento farmacológico , Femenino , Humanos , Masculino , Metotrexato/uso terapéutico , Persona de Mediana Edad , Perú/epidemiología , Prevalencia , Psoriasis/tratamiento farmacológico , Estudios Retrospectivos , Índice de Severidad de la Enfermedad
10.
Curr Rheumatol Rep ; 13(4): 324-37, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21633837

RESUMEN

Systemic lupus erythematosus (SLE) is an autoimmune disease that disproportionately affects women of childbearing age during their most productive years. Current therapeutic measures have improved patient survival; however, the impact of interventions on general and specific domains of health-related quality of life requires further study. Medical Outcomes Survey Short Form 36 (SF-36), the most commonly used measure, has been included in some SLE randomized controlled trials, but the observed effect sizes were generally small and in some cases negligible. An SLE patient's quality of life is known to be significantly worse than that of someone in the general population and perhaps worse than those with most other common chronic diseases. SF-36, although useful as a general measure, may not be the most sensitive way to gauge changes perceived by patients with SLE. Ongoing trials and observational longitudinal studies using lupus-specific health-related quality-of-life measures may help better determine health-related quality-of-life responses and determine the domains most amenable to interventions.


Asunto(s)
Estado de Salud , Lupus Eritematoso Sistémico/psicología , Lupus Eritematoso Sistémico/terapia , Calidad de Vida , Adaptación Psicológica , Terapias Complementarias , Femenino , Humanos , Lupus Eritematoso Sistémico/fisiopatología , Ensayos Clínicos Controlados Aleatorios como Asunto , Perfil de Impacto de Enfermedad , Resultado del Tratamiento
11.
Curr Rheumatol Rep ; 13(4): 360-8, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21552999

RESUMEN

Psoriasis and its related manifestations, including psoriatic arthritis, are prevalent disorders in the Western world, particularly among Caucasians. The study of these disorders in Latin America lags way behind the study of other more common rheumatic disorders, such as rheumatoid arthritis and systemic lupus erythematosus. From the scarce evidence available, however, it appears that the prevalence and incidence of psoriasis and psoriatic arthritis are lower than in other parts of the Western world and almost negligible among natives from the Andean region, although confirmatory epidemiologic studies are lacking.


Asunto(s)
Artritis Psoriásica/epidemiología , Artritis Psoriásica/etiología , Artritis Psoriásica/fisiopatología , América Central/epidemiología , Predisposición Genética a la Enfermedad , Humanos , Incidencia , Prevalencia , Psoriasis/epidemiología , Psoriasis/etiología , Psoriasis/fisiopatología , Índice de Severidad de la Enfermedad , América del Sur/epidemiología
12.
J Rheumatol ; 38(5): 868-73, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21324961

RESUMEN

OBJECTIVE: To test the interrater and intrarater reliability of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Responder Index (SRI-50), an index designed to measure ≥ 50% improvement in disease activity between visits in patients with systemic lupus erythematosus. METHODS: This was a multicenter, cross-sectional study with raters from Canada, the United Kingdom, and Argentina. Patient profile scenarios were derived from real adult patients. Ten rheumatologists from university and community hospitals and postdoctoral rheumatology fellows participated. An SRI-50 data retrieval form was used. Each rheumatologist scored SLEDAI-2K at the baseline visit and SRI-50 on followup visit, for the same patients, on 2 occasions 2 weeks apart. Physician global assessment (PGA) was determined on a numerical scale at baseline visit and a Likert scale on followup visit. Interrater and intrarater reliability was assessed using intraclass correlation coefficient (ICC) and kappa statistics whenever applicable. RESULTS: Forty patient profiles were created. The ICC performed on 80 patient profiles for interrater ranged from 1.00 for SLEDAI-2K and SRI-50 to 0.96 for PGA. The intrarater ICC for SLEDAI-2K, SRI-50, and PGA scores ranged from 1.00 to 0.86. Substantial agreement was determined for the interrater Likert scale, with a kappa statistic of 0.57. CONCLUSION: The SRI-50 is reliable to assess ≥ 50% improvement in lupus disease activity. Use of the SRI-50 data retrieval form is essential to ensure optimal performance of the SRI-50. SRI-50 can be used by both rheumatologists and trainees and performs equally well in trained as well as untrained rheumatologists.


Asunto(s)
Lupus Eritematoso Sistémico/diagnóstico , Adulto , Argentina , Canadá , Estudios Transversales , Femenino , Humanos , Lupus Eritematoso Sistémico/fisiopatología , Masculino , Persona de Mediana Edad , Variaciones Dependientes del Observador , Dimensión del Dolor , Reproducibilidad de los Resultados , Índice de Severidad de la Enfermedad , Reino Unido
13.
Curr Rheumatol Rep ; 12(4): 237-49, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20461481

RESUMEN

Although the survival rate for systemic lupus erythematosus (SLE) has improved dramatically during the past 50 years, the quality of life of patients afflicted with this disease remains poor. Currently existent measures of disease activity and damage in SLE do not capture the patient's perspective and health-related quality of life (HRQoL). Most studies in SLE pertaining to HRQoL are from developed Western societies, with only a few from others. These studies have been conducted predominantly in women and using the Medical Outcomes Survey Short Form 36, a generic HRQoL instrument that has been shown not to be sensitive to change in lupus. Existent lupus-specific HRQoL measures have not yet been used in SLE clinical trials. New HRQoL research tools are currently undergoing validation in different countries, languages, and cultural settings, which may help dissect the underlying role of socioeconomic status and specific disease-related features that impact SLE-related quality of life.


Asunto(s)
Comparación Transcultural , Estado de Salud , Lupus Eritematoso Sistémico/etnología , Lupus Eritematoso Sistémico/psicología , Calidad de Vida , Ensayos Clínicos como Asunto , Femenino , Humanos , Masculino , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
14.
Rev. Fac. Cienc. Méd. (Córdoba) ; Rev. Fac. Cienc. Méd. (Córdoba);55(1/2): 27-30, 1997. tab, graf
Artículo en Español | LILACS | ID: lil-231899

RESUMEN

El objetivo de este estudio fue observar las principales características clínicas y epidemiológicas de la presentación de la diarrea aguda del adulto en un hospital público de la ciudad de Córdoba. Para su realización se incluyeron todos los pacientes mayores de 14 años que concurrieron a la Guardia Central del Hospital Nacional de Clínicas con diarrea aguda durante los períodos A(15-12-89 al 15-3-90), B(15-12-93 al 15-3-94), y C(15-12-94 al 15-3-95). El total de pacientes incluídos en los 3 períodos fue de 594: 337 mujeres (65,7 por ciento) y 257 varones; 143 consultaron en el período A, 250 en el B y 201 en el C. El promedio + DE de edad fue 34,6 + 13,3 años y de deposiciones diarias al momento de la consulta 7,3 + 4,7. El 86,1 por ciento presentó materia fecal de consistencia líquida durante el pisodio, 89,6 por ciento dolor abdominal, 44,7 por ciento vómitos y 18,8 por ciento sangre. El porcentaje de pacientes que concurrieron al hospital por diarrea aguda en relación al total de consultas aumentó del período A (2,47 por ciento) al B (3,61 por ciento), p=0,002 y disminuyó del período B al C(2,85 por ciento), p=0,01. Los promedios + DE de días transcurridos desde el inicio del cuadro hasta la consulta fueron 3,5 + 2,7 + 2,3 y 2,9 + 3,5 en los períodos A, B y C, diferencia estadísticamente significativa entre A y B, p<0,01. Presentó moco en la material fecal el 36,2 por ciento, 21.1 por ciento y 23,1 por ciento de los pacientes en los períodos A, B y C (p=0,01) y fiebre constatada el 61,1 por ciento, 48,1 por ciento y 48,5 por ciento respectivamente (p=0,04). El 27.1 por ciento de los coprocultivos resultó positivo en el período A, 17,6 por ciento en el B y 11,5 por ciento en el C; diferencia entre a y C: p=0,008. Se concluye que en un hospital público de la ciudad de Córdoba la diarrea aguda del adulto es causa frecuente de consulta, constatándose modificaciones de las características clínico-epidemiológicas en los ultimos años.


Asunto(s)
Adulto , Femenino , Humanos , Adolescente , Diarrea/epidemiología , Enfermedad Aguda , Argentina/epidemiología , Intervalos de Confianza , Diarrea/diagnóstico
15.
Rev. Fac. Cienc. Méd. [Córdoba] ; 55(1/2): 27-30, 1997. tab, gra
Artículo en Español | BINACIS | ID: bin-16370

RESUMEN

El objetivo de este estudio fue observar las principales características clínicas y epidemiológicas de la presentación de la diarrea aguda del adulto en un hospital público de la ciudad de Córdoba. Para su realización se incluyeron todos los pacientes mayores de 14 años que concurrieron a la Guardia Central del Hospital Nacional de Clínicas con diarrea aguda durante los períodos A(15-12-89 al 15-3-90), B(15-12-93 al 15-3-94), y C(15-12-94 al 15-3-95). El total de pacientes incluídos en los 3 períodos fue de 594: 337 mujeres (65,7 por ciento) y 257 varones; 143 consultaron en el período A, 250 en el B y 201 en el C. El promedio + DE de edad fue 34,6 + 13,3 años y de deposiciones diarias al momento de la consulta 7,3 + 4,7. El 86,1 por ciento presentó materia fecal de consistencia líquida durante el pisodio, 89,6 por ciento dolor abdominal, 44,7 por ciento vómitos y 18,8 por ciento sangre. El porcentaje de pacientes que concurrieron al hospital por diarrea aguda en relación al total de consultas aumentó del período A (2,47 por ciento) al B (3,61 por ciento), p=0,002 y disminuyó del período B al C(2,85 por ciento), p=0,01. Los promedios + DE de días transcurridos desde el inicio del cuadro hasta la consulta fueron 3,5 + 2,7 + 2,3 y 2,9 + 3,5 en los períodos A, B y C, diferencia estadísticamente significativa entre A y B, p<0,01. Presentó moco en la material fecal el 36,2 por ciento, 21.1 por ciento y 23,1 por ciento de los pacientes en los períodos A, B y C (p=0,01) y fiebre constatada el 61,1 por ciento, 48,1 por ciento y 48,5 por ciento respectivamente (p=0,04). El 27.1 por ciento de los coprocultivos resultó positivo en el período A, 17,6 por ciento en el B y 11,5 por ciento en el C; diferencia entre a y C: p=0,008. Se concluye que en un hospital público de la ciudad de Córdoba la diarrea aguda del adulto es causa frecuente de consulta, constatándose modificaciones de las características clínico-epidemiológicas en los ultimos años. (AU)


Asunto(s)
Adulto , Femenino , Humanos , Estudio Comparativo , Adolescente , Diarrea/epidemiología , Argentina/epidemiología , Enfermedad Aguda , Diarrea/diagnóstico , Intervalos de Confianza
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA